CN107412555B - A medicine for treating ovulation disorder and preparation method thereof - Google Patents
A medicine for treating ovulation disorder and preparation method thereof Download PDFInfo
- Publication number
- CN107412555B CN107412555B CN201710251773.0A CN201710251773A CN107412555B CN 107412555 B CN107412555 B CN 107412555B CN 201710251773 A CN201710251773 A CN 201710251773A CN 107412555 B CN107412555 B CN 107412555B
- Authority
- CN
- China
- Prior art keywords
- medicine
- treatment
- ovulation
- maca
- chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine for treating ovulation failure and a preparation method thereof. The invention discloses a medicine for treating ovulation failure, which is prepared from maca, epimedium herb, malaytea scurfpea fruit, rhizoma polygonati, Chinese yam, prepared rehmannia root, bulbus fritillariae cirrhosae, spina gleditsiae, peach kernel and Chinese angelica according to the mass part ratio of 10: (2.4-15): (2.4-15): (4-20): (3.6-20): (4-20): (3.6-20): (2-15): (1.2-15): (3.6-20). Experiments prove that the medicine can treat patients with WHO II type ovulation failure and elderly ovulation failure, the percentage of the patients with the treatment effect respectively reaches 92.6% and 96.3%, and the medicine has the advantages of obvious treatment effect on polycystic ovary, ovarian hypofunction and elderly second-fetus, strong pertinence, obvious curative effect and no toxic or side effect.
Description
Technical Field
The invention relates to a traditional Chinese medicine prescription in the field of traditional Chinese medicines and a preparation method thereof, in particular to a medicine for treating ovulation failure and a preparation method thereof.
Background
Infertility is a common and frequently encountered medical disease, and is the third disease with incidence rate after cardiovascular diseases and malignant tumors. The non-contraceptive of women after marriage is called primary infertility or the non-pregnant women who live a year after marriage are called secondary infertility, and the non-contraceptive women who live a year after pregnancy is called secondary infertility.
Ovulation failure is one of the main causes of female infertility, accounting for about 30-40% of all infertility patients, and mainly means that women cannot discharge normal eggs, including mature egg development failure and egg discharge failure. The medical manifestations are irregular menstruation, irregular cycle, amenorrhea and sterility. Diagnosis of ovulation disorder is made with at least two of the following four items: 1. continuously measuring and recording the basal body temperature, and presenting a single phase for more than 3 months; 2. b ultrasonic follicle in the middle period of menstruation monitors that no ovulation occurs in the menstruation period of 3 months continuously; 3. no ellipsoid crystal is found in cervical mucus examination; 4. the blood progesterone levels in the luteal phase are lower than normal.
Abnormal serum gonadotropin and estradiol levels may lead to ovulation disorders. The WHO (World Health Organization) has classified the ovulation failure into type I-III. Type I: hypothalamic-pituitary failure, hypogonadotropic hypogonadism, i.e., hypogonadotropic hypogonadism, does not show space occupying lesion in the hypothalamic-pituitary area, and is manifested as low FSH, low E2, and diseases such as hypothalamic amenorrhea (stress, weight loss, anorexia nervosa), etc.; type II: hypothalamo-pituitary dysfunction, relatively normal or elevated gonadotropin levels but with certain endogenous estrogens resulting from hypothalamic-pituitary dysfunction, manifested as normal FSH, normal E2, normal PRL, such as menstrual disorder, polycystic ovary syndrome, etc.; type III: ovarian failure, high gonadotropic hypogonadism, is caused by ovarian failure and is manifested by high FSH, low E2 and low PRL, which often occurs in menopausal women. Ovulation disorders are frequently of the WHO type II and are frequently observed in patients with polycystic ovarian syndrome (PCOS), with type II ovulation disorders accounting for approximately 97% of the ovulation disorders. At present, the Chinese patent medicines commonly used for treating the ovulation failure in medicine are few in variety, weak in pertinence and unobvious in treatment effect, and medicines with strong pertinence, obvious in curative effect and no toxic or side effect for treating the ovulation failure are urgently needed.
Disclosure of Invention
The object of the present invention is to provide a practical and effective drug for treating ovulation failure.
The medicine for treating the ovulation failure is prepared from the following medicinal materials: herba Epimedii, fructus Psoraleae, maca, radix rehmanniae Preparata, rhizoma Polygonati, and rhizoma Dioscoreae. Wherein, the mass part ratio of the maca, the epimedium herb, the malaytea scurfpea fruit, the sealwort, the yam and the prepared rehmannia root can be 10: (2.4-15): (2.4-15): (4-20): (3.6-20): (4-20), specifically 10: (6-15): (6-15): (10-20): (9-20): (10-20) or 25: (6-15): (6-15): (10-20): (9-20): (10-20).
Further, the components can also comprise the following medicinal materials: bulbus Fritillariae Cirrhosae, spina Gleditsiae, and semen Persicae. Wherein, the mass part ratio of maca, epimedium herb, malaytea scurfpea fruit, rhizoma polygonati, yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae and peach seed can be 10: (2.4-15): (2.4-15): (4-20): (3.6-20): (4-20): (3.6-20): (2-15): (1.2-15), specifically 10: (6-15): (6-15): (10-20): (9-20): (10-20): (9-20): (5-15): (3-15) or 25: (6-15): (6-15): (10-20): (9-20): (10-20): (9-20): (5-15): (3-15).
Furthermore, the components can be the following medicinal materials: herba Epimedii, fructus Psoraleae, maca, radix rehmanniae Preparata, rhizoma Polygonati, rhizoma Dioscoreae, Bulbus Fritillariae Cirrhosae, spina Gleditsiae, semen Persicae, and radix Angelicae sinensis.
Wherein, the mass part ratio of maca, epimedium herb, malaytea scurfpea fruit, rhizoma polygonati, yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae, peach kernel and angelica can be 10: (2.4-15): (2.4-15): (4-20): (3.6-20): (4-20): (3.6-20): (2-15): (1.2-15): (3.6-20).
Specifically, the mass ratio of maca, epimedium herb, malaytea scurfpea fruit, sealwort, Chinese yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae, peach kernel and Chinese angelica can be 10: (6-15): (6-15): (10-20): (9-20): (10-20): (9-20): (5-15): (3-15): (9-20) or 25: (6-15): (6-15): (10-20): (9-20): (10-20): (9-20): (5-15): (3-15): (9-20).
In the above medicine, each medicinal material can be a Chinese medicinal decoction piece of the corresponding medicinal material, and can also be a Chinese medicinal granule prepared from the corresponding Chinese medicinal decoction pieces.
In the above drugs, the dosage form of the drug can be a gastrointestinal administration dosage form or a parenteral administration dosage form.
The gastrointestinal administration dosage form can be powder, tablet, granule, capsule, pill, solution, emulsion or suspension. The parenteral administration dosage form may be specifically an injection.
The preparation method of the medicine can comprise the following steps 1) or 2) or 3):
1) the medicine is prepared from epimedium, fructus psoraleae, maca, prepared rehmannia root, rhizoma polygonati and Chinese yam;
2) the medicine is prepared from herba Epimedii, fructus Psoraleae, maca, radix rehmanniae Preparata, rhizoma Polygonati, rhizoma Dioscoreae, Bulbus Fritillariae Cirrhosae, spina Gleditsiae and semen Persicae;
3) the medicine is prepared from epimedium, fructus psoraleae, maca, prepared rehmannia root, rhizoma polygonati, Chinese yam, bulbus fritillariae cirrhosae, spina gleditsiae, peach kernel and angelica.
The preparation method of the medicine also belongs to the protection scope of the invention, and the method comprises the following steps 1) or 2) or 3):
1) the medicine is prepared from epimedium, fructus psoraleae, maca, prepared rehmannia root, rhizoma polygonati and Chinese yam;
2) the medicine is prepared from herba Epimedii, fructus Psoraleae, maca, radix rehmanniae Preparata, rhizoma Polygonati, rhizoma Dioscoreae, Bulbus Fritillariae Cirrhosae, spina Gleditsiae and semen Persicae;
3) the medicine is prepared from epimedium, fructus psoraleae, maca, prepared rehmannia root, rhizoma polygonati, Chinese yam, bulbus fritillariae cirrhosae, spina gleditsiae, peach kernel and angelica.
In the method 1), the ratio of the maca, the epimedium herb, the fructus psoraleae, the rhizoma polygonati, the Chinese yam and the prepared rehmannia root in parts by weight can be 10: (2.4-15): (2.4-15): (4-20): (3.6-20): (4-20).
In the method 2), the ratio of maca, epimedium herb, malaytea scurfpea fruit, sealwort, Chinese yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae and peach kernel in parts by mass can be 10: (2.4-15): (2.4-15): (4-20): (3.6-20): (4-20): (3.6-20): (2-15): (1.2-15).
In the method 3), the ratio of maca, epimedium herb, malaytea scurfpea fruit, sealwort, Chinese yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae, peach kernel and Chinese angelica can be 10: (2.4-15): (2.4-15): (4-20): (3.6-20): (4-20): (3.6-20): (2-15): (1.2-15): (3.6-20).
Specifically, the mass ratio of maca, epimedium herb, malaytea scurfpea fruit, sealwort, Chinese yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae, peach kernel and Chinese angelica can be 10: (6-15): (6-15): (10-20): (9-20): (10-20): (9-20): (5-15): (3-15): (9-20) or 25: (6-15): (6-15): (10-20): (9-20): (10-20): (9-20): (5-15): (3-15): (9-20).
In the above method, each of the herbs can be a Chinese herbal piece of the corresponding herb, or a Chinese herbal granule prepared from the corresponding Chinese herbal piece.
The above process can be carried out by conventional Chinese medicinal preparation equipment, such as Holly brand TCM Dispenser. The traditional Chinese medicine preparation equipment can comprise a prescription management system, a medicine warehouse, a dispensing cabinet, a particle subpackaging dosage platform and an automatic packaging machine.
Also included in the scope of the present invention are products containing said medicament, said products having at least one of the following functions Y1) -Y6):
y1) for the treatment of ovulation disorders;
y2) for the treatment of female infertility;
y3) for the treatment of menstrual disorders;
y4) promoting follicular growth, development and/or maturation;
y5) to promote ovulation;
y6) regulates endocrine function of the hypothalamic-pituitary-ovarian axis.
The product can use the drug as the active component, and can also use the drug together with other substances with the same function as the active component. The product may be a medicament.
The application of the medicine in the preparation of any one of the following products for indication also belongs to the protection scope of the invention:
y1) for the treatment of ovulation disorders;
y2) for the treatment of female infertility;
y3) for the treatment of menstrual disorders;
y4) promoting follicular growth, development and/or maturation;
y5) to promote ovulation;
y6) regulates hypothalamic-pituitary-ovarian axis endocrine function.
Also within the scope of the invention is a method of treatment of an ovulation disorder comprising effecting treatment of the ovulation disorder with the medicament.
In the present invention, the ovulation failure may be, in particular, ovulation failure caused by menstrual disorder. Menstrual disorder is manifested by irregular cycles, abnormal menstrual bleeding, or abdominal pain and general symptoms before and during menstruation.
The traditional Chinese medicine decoction pieces are prepared by soaking traditional Chinese medicines according to the traditional Chinese medicine theory and the traditional Chinese medicine processing method, and can be directly used for traditional Chinese medicine clinical application.
Experiments prove that the medicine for treating the ovulation failure can treat patients with WHO II type ovulation failure and elderly patients with the ovulation failure, the percentage of the patients with the ovulation failure respectively reaches 92.6% and 96.3%, and the medicine for treating the ovulation failure has the advantages of obvious treatment effects on polycystic ovary, ovarian hypofunction and elderly second-fetus, strong pertinence, obvious curative effect and no toxic or side effect; the medicine of the invention can be prepared into dosage forms such as dripping pills and the like which are convenient to carry and take, and is suitable for large-scale popularization.
Detailed Description
The present invention is described in further detail below with reference to specific embodiments, which are given for the purpose of illustration only and are not intended to limit the scope of the invention. The experimental procedures in the following examples are conventional unless otherwise specified. Materials, reagents, instruments and the like used in the following examples are commercially available unless otherwise specified.
Example 1 preparation of a Compound Chinese medicinal preparation for treating ovulation failure (drug for treating ovulation failure)
The embodiment provides a traditional Chinese medicine compound preparation A and a traditional Chinese medicine compound preparation B for treating ovulation failure, wherein the traditional Chinese medicine compound preparation A is prepared from maca, epimedium herb, malaytea scurfpea fruit, rhizoma polygonati, Chinese yam, prepared rehmannia root, bulbus fritillariae cirrhosae, spina gleditsiae, peach kernel and Chinese angelica according to the mass part ratio of (10-25): (6-15): (6-15): (10-20): (9-20): (10-20): (9-20): (5-15): (3-15): (9-20) is prepared by Chinese medicinal preparation equipment, and the Chinese medicinal compound preparation B is prepared from maca, epimedium herb, fructus psoraleae, rhizoma polygonati, Chinese yam and prepared rehmannia root according to the mass part ratio of (10-25): (6-15): (6-15): (10-20): (9-20): (10-20) is prepared by traditional Chinese medicine preparation equipment. Wherein, maca, epimedium herb, malaytea scurfpea fruit, rhizoma polygonati, Chinese yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae, peach kernel and Chinese angelica are single traditional Chinese medicine granules prepared from corresponding traditional Chinese medicine decoction pieces; the traditional Chinese medicine preparation equipment comprises a prescription management system, a medicine warehouse, a dispensing cabinet, a particle subpackaging dosage platform and an automatic packaging machine. The preparation method of the traditional Chinese medicine compound preparation comprises the following steps:
1. preparation of single Chinese medicine granule
The traditional Chinese medicine granules of maca, epimedium herb, malaytea scurfpea fruit, sealwort, Chinese yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae, peach seed and angelica are respectively prepared from traditional Chinese medicine decoction pieces of maca, epimedium herb, malaytea scurfpea fruit, sealwort, yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae, peach seed and angelica.
2. Preparation of Chinese medicine compound preparation
2.1 Chinese medicinal preparation A
The traditional Chinese medicine compound preparation A is a traditional Chinese medicine granule prepared from traditional Chinese medicine granules of maca, epimedium herb, malaytea scurfpea fruit, rhizoma polygonati, Chinese yam, prepared rehmannia root, bulbus fritillariae cirrhosae, spina gleditsiae, peach kernel and angelica sinensis by utilizing Holly brand TCM Dispenser, and different traditional Chinese medicine compound preparations A and the formula thereof are as follows:
the traditional Chinese medicine granules of maca, epimedium herb, malaytea scurfpea fruit, rhizoma polygonati, Chinese yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae, peach kernel and Chinese angelica are prepared according to the mass part ratio of 10: 6: 6: 10: 9: 10: 9: 5: 3: 9, recording the obtained Chinese medicinal compound preparation as a Chinese medicinal compound preparation A1;
the traditional Chinese medicine granules of maca, epimedium herb, malaytea scurfpea fruit, rhizoma polygonati, Chinese yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae, peach kernel and Chinese angelica are prepared according to the mass part ratio of 10: 15: 15: 20: 20: 20: 20: 15: 15: 20, recording the obtained traditional Chinese medicine compound preparation as a traditional Chinese medicine compound preparation A2;
the traditional Chinese medicine granules of maca, epimedium herb, malaytea scurfpea fruit, rhizoma polygonati, Chinese yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae, peach kernel and Chinese angelica are prepared according to the mass part ratio of 25: 6: 6: 10: 9: 10: 9: 5: 3: 9 (namely 10: 2.4: 2.4: 4: 3.6: 4: 3.6: 2: 1.2: 3.6) is marked as a Chinese medicinal compound preparation A3;
the traditional Chinese medicine granules of maca, epimedium herb, malaytea scurfpea fruit, rhizoma polygonati, Chinese yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae, peach kernel and Chinese angelica are prepared according to the mass part ratio of 25: 15: 15: 20: 20: 20: 20: 15: 15: 20 (namely 10: 6: 6: 8: 8: 8: 8: 6: 6: 8) is recorded as the Chinese herbal compound preparation A4.
2.2 Compound preparation B of Chinese traditional medicine
The Chinese medicinal compound preparation B is a Chinese medicinal granule prepared from maca, epimedium herb, fructus psoraleae, rhizoma polygonati, Chinese yam and prepared rehmannia root by using Holly brand TCM Dispenser, and different Chinese medicinal compound preparations B and the formula thereof are as follows:
the traditional Chinese medicine granules of maca, epimedium herb, malaytea scurfpea fruit, rhizoma polygonati, Chinese yam and prepared rehmannia root are mixed according to the mass part ratio of 10: 6: 6: 10: 9: 10, recording the obtained Chinese medicinal compound preparation as a Chinese medicinal compound preparation B1;
the traditional Chinese medicine granules of maca, epimedium herb, malaytea scurfpea fruit, rhizoma polygonati, Chinese yam and prepared rehmannia root are mixed according to the mass part ratio of 25: 6: 6: 10: 9: the Chinese herbal compound preparation obtained by 10 (namely 10: 2.4: 2.4: 4: 3.6: 4) is marked as a Chinese herbal compound preparation B2.
Example 2A Compound preparation A and B can be used for treating ovulation disorder
A Chinese medicinal composition for treating ovulation failure
1. Study object
528 female patients with ovulation failure (experimental group 1), of which 219 were WHO type ii patients and 309 were elderly (older than 35 years).
Of these 528 patients with ovulation failure, 118 in 21-25 years of age were randomized into four groups, namely group A1 (29), group A2 (30), group A3 (29) and group A4 (30);
113 cases were shared between 26 and 30 years old, and were randomized into four groups, i.e., group B1 (29 cases), group B2 (28 cases), group B3 (28 cases), and group B4 (28 cases);
31-35 years old, 106 cases were randomized into four groups, namely group C1 (25 cases), group C2 (26 cases), group C3 (25 cases) and group C4 (26 cases);
36-40 years old, 116 cases were kept, and were randomly divided into four groups, i.e., group D1 (29 cases), group D2 (29 cases), group D3 (29 cases), and group D4 (29 cases);
75 cases were kept at age 41-45, and were randomized into four groups, i.e., pentane 1 (19 cases), pentane 2 (19 cases), pentane 3 (19 cases), and pentane 4 (18 cases).
2. Treatment of
528 cases of patients with ovulation failure are treated by using a traditional Chinese medicine compound preparation A, wherein the group A1, the group B1, the group C1, the group D1 and the group E1 are treated by using the traditional Chinese medicine compound preparation A1 in the embodiment 1; the group A2, the group B2, the group C2, the group D2 and the group E2 are all treated by using the Chinese herbal compound preparation A2 in the embodiment 1; the group A3, the group B3, the group C3, the group D3 and the group E3 are all treated by using the traditional Chinese medicine compound preparation A3 in the embodiment 1; the group A4, group B4, group C4, group D4 and group E4 were all treated with the herbal combination formulation A4 of example 1.
The treatment is divided into 3 treatment courses, each treatment course is a menstrual cycle (about 28-35 days), and each treatment course is taken once every day in the morning and at night with warm water, and each treatment course is taken one packet (6 g).
Recording the treatment condition of the patient before the next menstruation at the end of each treatment course, if the menstruation appears after ovulation, carrying out corresponding pregnancy test and B-ultrasonic examination, generally testing the positive of blood B-HCG during the menstruation stopping period, and then, confirming that the pulse of the gestational sac and the fetal heart in the uterine cavity is confirmed to be the confirmed pregnancy by the B-ultrasonic examination.
The results show that after all treatment courses are finished, the treatment effects of different Chinese medicinal compound preparations A have no obvious difference in the same age, namely the number of cured patients and the number of treatment patients with obvious effects have no obvious difference between treatment groups of different Chinese medicinal compound preparations. The therapeutic effects are shown in table 1, table 2 and table 3.
TABLE 1 therapeutic effect of Chinese medicinal composition on ovulation failure
TABLE 2 therapeutic effect of the compound Chinese medicinal preparation on ovulation failure patients of different ages
TABLE 3 relationship between the treatment effect and the treatment course
| Course of treatment | Cure (example) | Obvious therapeutic effect (example) | Is effective in treating | Treatment failure (example) |
| 1 | 27 | 52 | 20 | 12 |
| 2 | 48 | 85 | 35 | 7 |
| 3 | 72 | 108 | 58 | 4 |
In tables 1-3, healing indicates that menstruation can be followed monthly (28-30 days), three BBT biphasic events within half a year, and B-ultrasound measures follicular maturation, ovulation. The general symptoms are obviously improved. Of these, approximately 30% of patients are cured of pregnancy (pregnancy test +, B-ultrasound sees pregnancy and fetal heart beat);
the treatment effect shows that the menstruation can be tidal according to the month (28-45 days), 2 times of BBT biphasic treatment is carried out in half a year, and the B ultrasonic wave detects the mature follicle and the ovulation. The general symptoms are obviously improved. Non-pregnant (pregnancy test-);
the treatment effect means that the menstruation of 30-60 days comes, 1 BBT biphasic condition occurs in half a year, B ultrasonic shows the growth of endometrium, one follicle is mature, and ovulation occurs. The general symptoms are improved. Non-pregnant (pregnancy test-);
treatment failure indicated that menstruation was menuing, but no BBT biphasic, follicular maturation and ovulation were not detected by ultrasound B. The general symptoms are improved. Not pregnant (pregnancy test-).
The results show that when the traditional Chinese medicine compound preparation A in the embodiment 1 is used for treating the ovulation failure, the percentage of the treatment effect in WHO II patients reaches 92.6 percent, and the percentage of the treatment effect in the elderly patients reaches 96.3 percent; the percentage of the treatment effect between the ages of 21 and 25 reaches 98.3 percent, the percentage of the treatment effect between the ages of 26 and 30 reaches 97.3 percent, the percentage of the treatment effect between the ages of 31 and 35 reaches 97.2 percent, the percentage of the treatment effect between the ages of 36 and 40 reaches 93.7 percent, the percentage of the treatment effect between the ages of 41 and 45 reaches 86.7 percent, and the percentage of the treatment effect in total reaches 95.6 percent; and as the treatment course increases, the percentage of the treatment effect increases. The data in Table 2 are represented by X2The test method is used for analyzing, and the percentage of patients with the same treatment effect in different age groups has no significant difference (p)>0.05), which shows that the Chinese medicinal compound preparation A can be used for treating patients with WHO II type ovulation failure and old patients with ovulation failure, and the treatment effect is not influenced by age. The data in Table 3 are represented by X2Assay method for analysis (p)<0.05), the more treatment courses, the better the curative effect. Statistical analysis on patients shows that the traditional Chinese medicine compound preparation can be used for treating ovulation failure.
Secondly, the Chinese herbal medicine compound preparation B treats the ovulation failure
In addition, 310 female patients with ovulation failure (experimental group 2) were randomly divided into two groups, 155 patients in each group, and the traditional Chinese medicine compound preparation B1 and the traditional Chinese medicine compound preparation B2 in the embodiment 1 were respectively used for treatment. The treatment is divided into 3 treatment courses, each treatment course is a menstrual cycle (about 28-35 days), and each treatment course is taken once every day in the morning and at night with warm water, and each treatment course is taken one packet (6 g).
After all treatment sessions, the therapeutic effect of each formulation was counted and the results are shown in table 4.
TABLE 4 therapeutic effect of different Chinese medicinal compound preparations
In table 4, the results of the compound Chinese medicinal preparation a 1 and the compound Chinese medicinal preparation a 2 are the results of the first step.
The data in Table 4 are represented by X2The test method is used for analysis, and the result shows that the Chinese medicinal compound preparation B1 and the Chinese medicinal compound preparation B2 have certain treatment effect on the ovulation failure: the cure and treatment significant percentage of patients of the Chinese medicinal compound preparation B1 is obviously lower than that of the Chinese medicinal compound preparation A1 (p)<0.05), but the percentage of patients who are both therapeutically effective is essentially the same; the cure and treatment significant percentage of patients of the Chinese medicinal compound preparation B2 is obviously lower than that of the Chinese medicinal compound preparation A2 (p)<0.05) but the percentage of patients who are both therapeutically effective is essentially the same. The indication shows that the Chinese medicine compound preparation B1 and the Chinese medicine compound preparation B2 can be used for treating ovulation failure.
Claims (7)
1. A medicine for treating ovulation failure is prepared from the following medicinal materials: herba Epimedii, fructus Psoraleae, maca, radix rehmanniae Preparata, rhizoma Polygonati, rhizoma Dioscoreae, Bulbus Fritillariae Cirrhosae, spina Gleditsiae, semen Persicae, and radix Angelicae sinensis;
wherein, the mass part ratio of maca, epimedium herb, malaytea scurfpea fruit, rhizoma polygonati, Chinese yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae, peach kernel and Chinese angelica is 10: (2.4-15): (2.4-15): (4-20): (3.6-20): (4-20): (3.6-20): (2-15): (1.2-15): (3.6-20).
2. The medicament of claim 1, wherein: the weight portion ratio of maca, epimedium herb, malaytea scurfpea fruit, sealwort, Chinese yam, prepared rehmannia root, unibract fritillary bulb, spina gleditsiae, peach seed and Chinese angelica is 10: (6-15): (6-15): (10-20): (9-20): (10-20): (9-20): (5-15): (3-15): (9-20) or 25: (6-15): (6-15): (10-20): (9-20): (10-20): (9-20): (5-15): (3-15): (9-20).
3. The medicament according to claim 1 or 2, characterized in that: all the medicinal materials are Chinese herbal pieces of corresponding medicinal materials;
and/or the dosage form of the medicine is a gastrointestinal administration dosage form or a non-gastrointestinal administration dosage form.
4. The medicament according to claim 1 or 2, characterized in that: the preparation method of the medicine comprises the following steps: the medicine is prepared from epimedium, fructus psoraleae, maca, prepared rehmannia root, rhizoma polygonati, Chinese yam, bulbus fritillariae cirrhosae, spina gleditsiae, peach kernel and angelica.
5. The method for preparing the medicament of any one of claims 1 to 4, comprising preparing the medicament from epimedium, psoralea corylifolia, maca, prepared rehmannia root, polygonatum rhizome, yam, fritillaria cirrhosa, spina gleditsiae, peach kernel and angelica.
6. Product containing a medicament according to any one of claims 1 to 4, said product having at least one of the following functions Y1) -Y6):
y1) for the treatment of ovulation disorders;
y2) for the treatment of female infertility;
y3) for the treatment of menstrual disorders;
y4) promoting follicular growth, development and/or maturation;
y5) to promote ovulation;
y6) regulates hypothalamic-pituitary-ovarian axis endocrine function.
7. Use of a medicament according to any one of claims 1 to 4 for the manufacture of a product for any one of the following indications:
y1) for the treatment of ovulation disorders;
y2) for the treatment of female infertility;
y3) for the treatment of menstrual disorders;
y4) promoting follicular growth, development and/or maturation;
y5) to promote ovulation;
y6) regulates hypothalamic-pituitary-ovarian axis endocrine function.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710251773.0A CN107412555B (en) | 2017-04-18 | 2017-04-18 | A medicine for treating ovulation disorder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710251773.0A CN107412555B (en) | 2017-04-18 | 2017-04-18 | A medicine for treating ovulation disorder and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107412555A CN107412555A (en) | 2017-12-01 |
| CN107412555B true CN107412555B (en) | 2020-11-10 |
Family
ID=60423694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710251773.0A Active CN107412555B (en) | 2017-04-18 | 2017-04-18 | A medicine for treating ovulation disorder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107412555B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112206324B (en) * | 2020-01-09 | 2022-11-22 | 上海交通大学医学院附属仁济医院 | Application of FHL2 in preparing medicine for treating polycystic ovarian syndrome ovulation disorder |
| CN117860861B (en) * | 2024-03-13 | 2024-05-28 | 云南省中医医院(云南中医药大学第一附属医院) | Acupoint plaster for promoting follicular development, and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105748916A (en) * | 2016-04-06 | 2016-07-13 | 柳州市妇幼保健院 | Medicine for treating ovulation failure |
-
2017
- 2017-04-18 CN CN201710251773.0A patent/CN107412555B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105748916A (en) * | 2016-04-06 | 2016-07-13 | 柳州市妇幼保健院 | Medicine for treating ovulation failure |
Non-Patent Citations (1)
| Title |
|---|
| 导师王秀云教授治疗PCOS经验选粹;凌娜;《中国优秀硕士学位论文全文数据库（电子期刊）医药卫生科技辑》;20051231(第5期);第E056-53页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107412555A (en) | 2017-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Chinese herbal medicines for treating osteoporosis | |
| WO2008119131A1 (en) | Herbal compositions and methods for treating female infertility | |
| WO2021253742A1 (en) | Application of wubi chinese yam pills in preparation of drug for treatment of premature ovarian insufficiency | |
| CN103223155B (en) | Medicament for treating postpartum hemorrhage | |
| CN107412555B (en) | A medicine for treating ovulation disorder and preparation method thereof | |
| CN103479887B (en) | Traditional Chinese medicine formula for treating climacteric dysfunctional uterine bleeding | |
| CN101138597B (en) | Traditional Chinese medicine preparation for preventing and controlling osteoporosis and method of preparing the same | |
| CN101664533B (en) | Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method | |
| CN115068578B (en) | Traditional Chinese medicine composition for treating insulin resistance type polycystic ovary syndrome and application thereof | |
| CN113599475B (en) | Middle-warming and kidney-tonifying composition for treating polycystic ovarian syndrome and preparation method and application thereof | |
| CN114470075A (en) | Traditional Chinese medicine composition for treating infertility and application thereof | |
| CN103919961B (en) | Middle and old age kidney-jing deficiency and kidney yang deficiency treatment traditional Chinese medicine preparation and preparation method thereof | |
| CN106421727A (en) | Traditional Chinese medicine composition for treating painful menstruation and preparation method and application thereof | |
| CN105213748A (en) | A kind of pharmaceutical composition for the treatment of female dimacteric syndrome and preparation method thereof | |
| CN113018367B (en) | Traditional Chinese medicine composition for treating thin endometrial hypomenorrhea and preparation method and application thereof | |
| CN109985125B (en) | Oral liquid for assisting pregnancy and preparation method thereof | |
| CN103751747B (en) | A kind of Chinese medicine of medicine colporrhagia due to abortion disease | |
| CN114159516B (en) | Traditional Chinese medicine composition for preventing and treating hashimoto thyroiditis and application thereof | |
| CN109646552B (en) | A Chinese medicinal composition for treating female livestock infertility, and its preparation method and medicinal preparation | |
| CN102698064A (en) | Medicament for treating climacteric syndrome | |
| CN106540168B (en) | Traditional Chinese medicine composition for treating kidney deficiency type irregular menstruation, amenorrhea and infertility as well as preparation method and application thereof | |
| CN105535658A (en) | Traditional Chinese medicine composition for treating dental ulcer and preparation method thereof | |
| CN103948794B (en) | Traditional Chinese medicine composition for treating hypofunction of ovary and preparation method of composition | |
| CN109152729B (en) | Single herb extract for treating PCOS (polycystic ovary syndrome) | |
| Kalam et al. | Formulation and Evaluation of Herbal Tablets for the Treatment of PCOD using Kanchnar and Shatavari |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |